SOD1 and amyotrophic lateral sclerosis: The SOD1-ASO, called Tofersen, was then tested in a phase I/II clinical trial, sponsored by Biogen (Biogen Inc., Cambridge, MA USA), (NCT02623699) that showed a reduction in SOD1 protein levels and a trend towards slowing clinical decline in treated SOD1-ALS patients (http://investors.biogen.com/news-releases/news-release-details/biogen-present-new-interim-data-its-phase-12-clinical-study).